Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia

• Published in: Digestive and liver disease 2021-07, Vol.53 (7), p.830-834
• Main Authors: Cococcioni, Lucia, Pensabene, Licia, El-Khouly, Sara, Chadokufa, Sibongile, McCartney, Sara, Saliakellis, Efstratios, Kiparissi, Fevronia, Borrelli, Osvaldo
• Format: Article
• Language: English
• Subjects: Administration, Intravenous; Adolescent; Anemia; Anemia, Iron-Deficiency - blood; Anemia, Iron-Deficiency - drug therapy; Anemia, Iron-Deficiency - etiology; Child; Child, Preschool; Female; Ferric carboxymaltose; Ferric Compounds - administration & dosage; Ferric Compounds - adverse effects; Ferritins - blood; Hemoglobins - drug effects; Humans; Hypophosphatemia; Hypophosphatemia - chemically induced; Hypophosphatemia - epidemiology; Inflammatory Bowel Diseases - blood; Inflammatory Bowel Diseases - complications; Iron - blood; Male; Maltose - administration & dosage; Maltose - adverse effects; Maltose - analogs & derivatives; Paediatric IBD; Phosphates - blood; Prevalence; Risk Factors; Severity of Illness Index; Treatment Outcome
• ISSN: 1590-8658; 1878-3562
• DOI: 10.1016/j.dld.2021.02.017

Although intravenous ferric carboxymaltose (FCM) is effective in treating iron deficiency anemia (IDA) in paediatric inflammatory bowel disease (pIBD), no data are available on its post-infusion related risks. We assessed the efficacy of FCM and the rate of post-infusion hypophosphatemia in a large cohort of children with IBD and IDA. All children with IBD with IDA treated with FCM over 5-year period were reviewed. Disease activity, biohumoral assessment and treatments were evaluated at baseline, 4–6 and 12 weeks after each infusion. 128 patients [median age at first infusion: 13 years] were identified, 81 (63.3%) were